Immunogen (IMGN) Misses Q1 EPS Views; Revenue Light of Consensus
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Immunogen (NASDAQ: IMGN) reported Q1 EPS of ($0.51), $0.13 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.66 million versus the consensus estimate of $21.12 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Liberty Tax (TAX) Misses Q2 EPS by 1c
- Ollie's Bargain Outlet (OLLI) Tops Q3 EPS by 3c, Offers FY Guidance
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!